Novartis gene therapy could get FDA approval in May
ZURICH: Novartis's gene therapy for spinal muscular atrophy (SMA) could be approved in May 2019 after the U.S. Food and Drug Administration agreed to an accelerated review of the Swiss drugmaker's treatment.
Novartis SMA treatment, now called Zolgensma, said on Monday it won FDA priority review after submitting clinical trial results for 15 patients, all of whom are alive at 24 months. The treatment may become one of the most-expensive one-time therapies ever, with Novartis pegging its value at $4-$5 million per patient.
Also Read: U.S. benefits manager baulks after Novartis values gene therapy at $4-5 million
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd